| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1461145710001641 |
| P698 | PubMed publication ID | 21299919 |
| P50 | author | Eduard Vieta | Q20090640 |
| P2093 | author name string | Mauricio Tohen | |
| Ross J Baldessarini | |||
| Ayşegül Yildiz | |||
| P2860 | cites work | Statistics review 5: Comparison of means | Q24797209 |
| Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis | Q27860511 | ||
| Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis | Q28189245 | ||
| Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study | Q28248076 | ||
| A rating scale for mania: reliability, validity and sensitivity | Q29619299 | ||
| Placebo effect in randomized, controlled studies of acute bipolar mania and depression | Q33895456 | ||
| Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder | Q34077437 | ||
| Lamotrigine: a review of its use in bipolar disorder | Q34228876 | ||
| A diagnostic interview: the schedule for affective disorders and schizophrenia | Q34269355 | ||
| National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders | Q34552405 | ||
| Valproate in the treatment of acute mania. A placebo-controlled study | Q34613045 | ||
| Research diagnostic criteria: rationale and reliability | Q34711463 | ||
| How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials | Q34733976 | ||
| Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen | Q34757926 | ||
| STATISTICAL TREATMENT OF THE LAW OF INITIAL VALUES (LIV) IN AUTONOMIC RESEARCH: A REVIEW AND RECOMMENDATION. | Q35409310 | ||
| The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate | Q35997742 | ||
| Psychobiology of the placebo response | Q36413187 | ||
| The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders | Q37558582 | ||
| A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania | Q38374723 | ||
| Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. | Q38385608 | ||
| A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. | Q38402146 | ||
| What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? | Q40055789 | ||
| Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration? | Q40085552 | ||
| Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials | Q42164457 | ||
| A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). | Q42930552 | ||
| A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder | Q43011129 | ||
| A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states | Q43258938 | ||
| Asenapine versus olanzapine in acute mania: a double-blind extension study | Q43260786 | ||
| Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 | ||
| Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification | Q43674377 | ||
| Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 | ||
| Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. | Q44877765 | ||
| Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial | Q44915194 | ||
| Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 | ||
| Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 | ||
| Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study | Q46202394 | ||
| Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. | Q46377270 | ||
| Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial | Q46596821 | ||
| Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 | ||
| Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial | Q46683979 | ||
| Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 | ||
| Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. | Q50877463 | ||
| Increasing rates of placebo response over time in mania studies. | Q53038901 | ||
| Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group | Q61480116 | ||
| A random-effects regression model for meta-analysis | Q72228939 | ||
| The use of placebos in randomized clinical trials of mood disorders: well justified, but improvements in design are indicated | Q73693569 | ||
| Introduction to Meta-Analysis | Q106417732 | ||
| P433 | issue | 7 | |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 863-875 | |
| P577 | publication date | 2011-02-07 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | Factors modifying drug and placebo responses in randomized trials for bipolar mania. | |
| P478 | volume | 14 |
| Q50110124 | A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania |
| Q37562207 | A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder |
| Q47696307 | A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. |
| Q35513153 | Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine |
| Q30760720 | Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study |
| Q44531492 | CANMAT Guidelines commentary: where does the evidence come from, and how can we use it for our patients? |
| Q48336238 | Declining efficacy in controlled trials of antidepressants: effects of placebo dropout |
| Q64067737 | Does Sex/Gender Play a Role in Placebo and Nocebo Effects? Conflicting Evidence From Clinical Trials and Experimental Studies |
| Q47616075 | Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. |
| Q35142737 | Korean Medication Algorithm Project for Bipolar Disorder: third revision |
| Q57471124 | Lithium, valproate, and carbamazepine prescribing patterns for long-term treatment of bipolar I and II disorders: A prospective study |
| Q48083750 | Making sense of DSM-5 mania with depressive features |
| Q40748349 | Net gain analysis, an addition to responder analysis--The case of antipsychotic treatment of acute mania |
| Q88427167 | Pharmacological treatment of adult bipolar disorder |
| Q91781840 | Placebo Effects in Psychotherapy: A Framework |
| Q35207492 | Placebo eff ects in psychiatry: mediators and moderators |
| Q38551120 | Placebo effects and their determinants in gastrointestinal disorders |
| Q34240696 | Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review |
| Q58120706 | Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for smoking cessation |
| Q35059000 | The effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs |
| Q41837093 | Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design |
Search more.